Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal study of 4SC-202 in combination with a checkpoint inhibitor in PD-(L)1 refractory patients with advanced Merkel cell carcinoma (MCC).

Trial Profile

A pivotal study of 4SC-202 in combination with a checkpoint inhibitor in PD-(L)1 refractory patients with advanced Merkel cell carcinoma (MCC).

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Domatinostat (Primary)
  • Indications Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 27 Dec 2018 According to a 4SC media release, this trial is expected to be initiated in 2H 2019.
    • 03 Jul 2018 According to the 4SC media release, this trial is expected to initiate in 2019.
    • 21 Mar 2018 According to a 4SC media release, taking data from SENSITIZE and EMERGE study, this study will be initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top